Windward Bio’s next-generation antibody medication for immunology caught the curiosity of Sanofi, which purchased shares in a personal placement alongside the biotech’s IPO. Windward’s lead drug candidate addresses the identical goal as a blockbuster bronchial asthma drug from companions Amgen and AstraZeneca.
The put up Windward Bio’s Inventory Market Debut Reels In $225M for Higher Biologic Medicine appeared first on MedCity Information.
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!
